Tharimmune, Inc. — Director's Dealing 2024

Oct 8, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tharimmune, Inc. (THAR)
CIK: 0001861657
Period of Report: 2024-08-09

Reporting Person: Appajosyula Sireesh (Director, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-10-08	Common Stock	P	5000	$1.93	Acquired	16364	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	38889	Indirect
Common Stock	304	Indirect

Footnotes

F1: 38,889 shares of common stock are held indirectly by Highpoint Pharmaceuticals, LLC and 304 shares of common stock are held by Channel BioConsulting LLC. The Reporting Person is the managing member of each of Highpoint Pharmaceuticals, LLC and Channel BioConsulting LLC and in such capacity has the right to vote and dispose of the securities held by such entities.